BioCentury | May 11, 2018
Finance

Seroquel stepping stone

...three CNS products that it markets in the U.S. and EU into emerging markets: a rivastigmine...
BioCentury | Sep 5, 2016
Company News

Qaam Pharmaceuticals, Axovant Sciences deal

...inhibitor. Axovant also plans to develop RVT-104 , a combination of glycopyrrolate and high-dose Exelon rivastigmine...
BioCentury | Sep 21, 2015
Company News

Acino sales and marketing update

...generic version of Exelon Patch rivastigmine from Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) in the U.S. Exelon Patch...
...PD). Alvogen Inc. (Pinebrook, N.J.) has exclusive marketing and distribution rights in the U.S. to rivastigmine...
BioCentury | Nov 17, 2014
Clinical News

Rivastach Patch rivastigmine regulatory update

...Ono submitted an application in Japan to amend the label of Rivastach Patch rivastigmine to treat mild...
...dose. The acetylcholinesterase (AChE) inhibitor is approved in the U.S. and EU under the name Exelon Patch...
...Co. Ltd. (Tokyo:4528), Osaka, Japan Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Rivastach Patch rivastigmine ( Exelon Patch...
BioCentury | Jun 23, 2014
Company News

Novartis A pharmaceuticals news

...acromegaly and neuroendocrine tumor drug Sandostatin octreotide acetate; autoimmune drug Neoral cyclosporine; neurology drug Exelon rivastigmine...
BioCentury | Sep 16, 2013
Emerging Company Profile

Cardeus: Microglia blockade

...as Exelon Patch rivastigmine from Novartis AG are marketed to treat dementia in AD and PD. Exelon...
BioCentury | Jul 15, 2013
Clinical News

Exelon Patch rivastigmine regulatory update

...FDA approved an sNDA from Novartis to expand the label of Exelon Patch rivastigmine transdermal patch to...
...a capsule or an oral solution formulation. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Exelon Patch rivastigmine...
BioCentury | May 6, 2013
Clinical News

Exelon Patch rivastigmine regulatory update

...disclosed in its 1Q13 earnings that EMA approved an expansion of the label of Exelon Patch rivastigmine...
...for both indications (see BioCentury, Feb. 4). Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Exelon Patch rivastigmine...
BioCentury | Feb 4, 2013
Clinical News

Exelon rivastigmine regulatory update

...earnings that EMA's CHMP issued a positive opinion recommending expansion of the label of Exelon Patch rivastigmine...
...approved in the EU for both indications. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Exelon rivastigmine...
BioCentury | Sep 10, 2012
Clinical News

Exelon Patch rivastigmine regulatory update

...FDA approved an sNDA to expand the label of Exelon Patch rivastigmine transdermal patch to include the...
...a capsule or an oral solution formulation. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Exelon Patch rivastigmine...
Items per page:
1 - 10 of 98